A Phase 3 interventional study of Transcatheter PFO closure and Oral Anticoagulant, Direct-Acting in Cryptogenic Ischemic Stroke and Patent Foramen Ovale, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 42 sites in France. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing Factor Xa inhibitors in Ischemic Stroke — 10 open to participants now, 10 under way, 6 of them phase 3. A drug class: Factor Xa inhibitors · Ischemic Stroke.
Among the 20 studies testing Factor Xa inhibitors in Ischemic Stroke, this one is the 13th largest by planned enrollment, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 12th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →10 of the 20 studies testing Factor Xa inhibitors in Ischemic Stroke are open now, in 10 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 75+
VA Office of Research and Development · Sites in United States
Ages 22+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
University of Zurich · Sites in Greece, Norway, Spain and 2 more countries
Ages 18+
Brazilian Clinical Research Institute
Ages 18+
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 60 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 11 · Phase 4 5
First in 2013; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 792 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 1,082 across the 20 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 20 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris: 9 open now, 11 under way, 4 of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is one of 7 that started in 2023, is one of 6 in phase 3, reaches primary completion later than 9 of the 10 other live ones, and was the 10th registered.
Assistance Publique - Hôpitaux de Paris’s Ischemic Stroke studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing Factor Xa inhibitors in Ischemic Stroke, from their registry updates:
Among Assistance Publique - Hôpitaux de Paris’s 20 in Ischemic Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80 years with a PFO with large shunt (> 20 microbubbles) or a PFO associated with an ASA (> 10 mm), and an otherwise unexplained ischemic stroke.
The CLOSE trial (NCT00562289, NEJM 2017) has unambiguously demonstrated the superiority of patent foramen ovale (PFO) closure over antiplatelet therapy alone in patients aged up to 60 years with a PFO associated with an atrial septal aneurysm (ASA) or a large right-to-left shunt (so-called "high-risk PFO"), and an otherwise unexplained ischemic stroke. Oral anticoagulant therapy is also a logical approach assuming that PFO-related strokes are due to paradoxical embolism which implies a venous source of embolism, or to direct embolization of a thrombus formed at the atrial level. The CLOSE trial also suggested that oral anticoagulants might reduce stroke recurrence compared to aspirin.
There is accumulating evidence that presence of a PFO is significantly associated with cryptogenic stroke in patients over 60 years. Cryptogenic ischemic strokes represent about one third of all ischemic strokes in patients older than 60 years. However, the optimal therapeutic strategy in patients older than 60 years with a PFO and an otherwise unexplained ischemic stroke is unknown, because these patients were excluded from randomized trials.
The hypothesis tested in this trial is that transcatheter PFO closure plus long-term antiplatelet therapy is superior to antiplatelet therapy alone and that oral anticoagulant therapy is superior to antiplatelet therapy to prevent recurrent stroke in patients aged 60 to 80 years who have a high-risk PFO and a recent otherwise unexplained ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of a PFO with at least 1 of the 2 following characteristics:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aspirin OR clopidogrel
Drug: Antiplatelet therapy
Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
Drug: Oral Anticoagulant, Direct-Acting
PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel
Procedure: Transcatheter PFO closure · Drug: Antiplatelet therapy
PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.
Also known as: •Each device for PFO closure must have the CE mark, •and be approved by the Interventional Cardiology Committee
Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
Time to recurrent stroke (ischemic or hemorrhagic fatal or non-fatal)
Stroke: sudden onset of focal neurological symptoms related to a disturbance of the cerebral circulation. Ischemic stroke : at least one of the following criteria: * Sudden onset of focal neurological symptoms with the presence of cerebral infarction in the appropriate territory on brain imaging (CT or MRI), regardless of the duration of symptoms (less than or more than 24 hours). * Sudden onset of focal neurological symptoms lasting more than 24 hours, with no apparent cause other than cerebral ischemia. Intracerebral hemorrhage: sudden onset of focal neurological symptoms with the presence of cerebral hemorrhage in the appropriate territory on brain imaging (CT or MRI), regardless of the duration of symptoms (less than or more than 24 hours) and regardless of the cause of the hemorrhage (spontaneous or secondary to trauma, tumour or another cause). Unknown type of stroke : the type of stroke cannot be determined with certainty and the symptoms last more than 24 hours.
Time frame: From date of randomization until the date of first recurrent stroke, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Time to disabling stroke
mRS score greater than or equal to 3, with an increase of at least 2 points compared to the last mRS score before the stroke.
Time frame: From date of randomization until the date of first recurrent disabling stroke, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Time to ischemic stroke
At least one of the following criteria: * Sudden onset of focal neurological symptoms with the presence of cerebral infarction in the appropriate territory on brain imaging (CT or MRI), regardless of the duration of symptoms (less than or more than 24 hours). * Sudden onset of focal neurological symptoms lasting more than 24 hours, with no apparent cause other than cerebral ischemia.
Time frame: From date of randomization until the date of first recurrent ischemic stroke, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Time to ischemic stroke or systemic embolism
Clinical features related to embolism usually affecting a limb, mesenteric, splenic, or renal artery. The diagnosis of embolism must be confirmed by appropriate investigations.
Time frame: From date of randomization until the date of first recurrent ischemic stroke or systemic embolism, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Time to transient ischemic attack,
Sudden onset of neurological symptoms, presumed to be ischemic, resolving in less than 24 hours, clearly attributable to focal involvement of the central nervous system (or of the eye) with no signs of a corresponding recent cerebral infarction on brain imaging. The diagnosis of TIA will be confirmed by a neurologist, considering clinical data and brain imaging (MRI with diffusion sequence is recommended).
Time frame: From date of randomization until the date of first transient ischemic attack, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Time to vascular death
* death related to a cardiac or vascular cause. * death due to hemorrhage. * death due to pulmonary embolism. * sudden death: death occurring in less than 24 hours, unexpectedly in a subject in apparent good health and whose condition was stable or was improving. * death with no documented non-vascular cause. * fatal stroke: death occurring within 30 days of a stroke (ischemic or hemorrhagic).
Time frame: From date of randomization until the date of vascular death, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Time to all-cause mortality
Vascular (see definition) or nonvascular death: death due to a documented non-vascular cause (infection, cancer, accident, suicide, etc.).
Time frame: From date of randomization until the date of death, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)
Quality of life score
Measured by using the European Quality Of Life (EQ-5D) auto-questionnaire. The digits for the five dimensions are combined into a 5-digit number that describes the patient's health state. The visual analogue scale (VAS) records the patient's self-rated health on a vertical axis from 0 (worst health) to 100 (best health)
Time frame: Every 6 months after randomization or up to 4 years (for the last patient included) to up to 8 years (for the first patient included)]
Time to fatal, life-threatening or major hemorrhage, including intracerebral and Intracranial hemorrhage
Life-threatening * Fatal hemorrhage. * Drop in hemoglobin by ≥ 5 g/dL (or drop in hematocrit by 15% or more in absolute value) * Symptomatic intracranial hemorrhage (confirmed by appropriate investigations, classified as cerebral hemorrhage, subarachnoid hemorrhage and subdural hematoma). * Transfusion ≥ 4 units of packed cells (or equivalent of whole blood)\*. Major * Transfusion ≤ 3 units of packed cells (or equivalent of whole blood)\*. * Requiring hospitalization (or prolonging hospitalization). * Requiring surgical treatment. * Intraocular hemorrhage with significant loss of vision. * Other hemorrhage responsible for significant disability according to the investigator.
Time frame: From date of randomization until the date of first fatal,life-threatening or major hemorrhage,including intracerebral and Intracranial hemorrhage,assessed from up to 4 years(for the last patient included) to up to 8 years(for the first patient included)
Proportion of success of device implantation, of the procedure and of PFO closure,
* Success of device implantation: deployment of the device in the appropriate place and removal of the placement system. * Success of the procedure: successful implantation with no complications before the patient's discharge. * Success of PFO closure: success of the procedure with no residual shunt or minimal residual shunt on echocardiography performed 6 months after the procedure.
Time frame: 6 months after PFO closure
Time to ischemic stroke recurrence according to the presence of a residual shunt
From control echocardiography after PFO closure to the end of the patient's follow-up
Time frame: From date of PFO closure until the date of first ischemic stroke recurrence, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included), according to the presence of residual shunt]
Time to new-onset atrial fibrillation
Atrial fibrillation lasting at least 30 seconds
Time frame: From date of randomization until the date of new-onset atrial fibrillation, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)]
Proportion of fatal, life-threatening or major procedure- or device-related complications
Life-threatening * Cardiac perforation with tamponade requiring emergency drainage. * Cerebral air embolism responsible for acute neurological disorders * Embolization of the device. * Life-threatening hematoma at the puncture site or retroperitoneal. * Complications of general anesthesia or TOE requiring intensive care and/or surgical operation. Major * Hemorrhage at the puncture site or retroperitoneal requiring transfusion or surgery. * Arteriovenous fistula, pseudoaneurysm requiring surgery. * Peripheral nerve lesion with disabling neurological deficit persisting \> 1 month. * Cardiac arrhythmias (particularly AF) during catheterization or post-procedure requiring treatment \>= 1 month. * Infective endocarditis. * Asymptomatic late thrombosis of the device. * Any device-related complication requiring surgery. * Any other complication related to the transcatheter treatment or anesthesia, considered to be major by the investigator.
Time frame: Within 4 weeks following the procedure (PFO closure)
Costs
Costs will be estimated from the viewpoint of the healthcare system (hospital admission, transportation, study interventions, emergency room visit without admission,consultations,imaging)
Time frame: Within 48 months after randomization
Incremental cost-utility ratio at 4 years (ICUR)
The incremental cost-utility ratio (ICUR) will be calculated as difference in costs (between groups)/difference in QALYs (Quality-Adjusted Life Year) between groups. The QALYs will be constructed with the EuroQoL-5D (EQ-5D) questionnaire and value sets
Time frame: Within 48 months after randomization
Plan to share: Yes — Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared
Supporting information: Study protocol, Informed consent form
Time frame: Two years after the last publication
Access criteria: Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered. Data sharing must respect the agreements made with funders. Teams wishing obtain IPD must meet the sponsor and PI team to present scientific (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasability and financial support will be discussed before mandatory contractual agreement. Processing of shared data must comply with European General Data Protection Regulation (GDPR).
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jul 2031, 96 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 96 months is above that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Factor Xa inhibitors
Assistance Publique - Hôpitaux de Paris →